About the Company
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HALO News
Should You Hold Halozyme Therapeutics (HALO)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2023 investor letter ...
Halozyme Therapeutics Inc HALO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Q4 2023 Halozyme Therapeutics Inc Earnings Call
Tram Bui; Head of IR & Corporate Communications; Halozyme Therapeutics, Inc. Helen Torley; President & CEO; Halozyme Therapeutics, Inc. Nicole LaBrosse; SVP & CFO ...
Halozyme Therapeutics: Q4 Earnings Snapshot
SAN DIEGO — SAN DIEGO — Halozyme Therapeutics Inc. (HALO) on Tuesday reported fourth-quarter profit of $85.4 million. The San Diego-based company said it had net income of 65 cents per share.
Halozyme Therapeutics, Inc. (HALO) Q4 2023 Earnings Call Transcript
Leading the call would be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Nicole LaBrosse, our Chief Financial Officer ...
Halozyme Therapeutics Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
Halozyme Therapeutics (HALO ... outperform the bottom 50% by a factor of more than 2 to 1. Revance Therapeutics, Inc. (RVNC), another stock in the same industry, has yet to report results for ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript
So any comments there would be helpful? Thanks. Helen Torley: Yes, we continue to see growing royalty contribution to Halozyme from sales HYQVIA. So Takeda has certainly continued to execute and ...
Loading the latest forecasts...